Cryptosporidium Infection
Conditions
Brief summary
This study aims to: 1. To evaluate the effectiveness of Immulant ® addition to standard treatment in reducing clinical symptoms of Cryptosporidiosis in immunocompromised children. 2. To measure the changes in parasite count in stool samples after treatment with Immulant ®. 3. To assess the safety and tolerability of Immulant ® in children participating in the study.
Detailed description
The present prospective study will be (open labelled) Randomized Clinical Trial and was approved by the Research Ethical Committee Of national nutritional institute. Oral and written consent will be obtained from all patients and controls after a full explanation of the study. A total of at least 60 immunocompromised children consecutively diagnosed with cryptosporidiosis were recruited from the outpatient clinic of National Nutritional Institute.
Interventions
Immulant ® (an extract derived from Echinacea purpurea plant)
Sponsors
Al-Azhar University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
open labelled randomized controlled
Eligibility
Sex/Gender
ALL
Age
5 Years to 12 Years
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of Cryptosporidiosis Disease * Age from 5-12 years * Immunocompromised children * Not receiving any drugs causing immunosuppression
Exclusion criteria
* Patients undergoing organ transplantation * Patients suffering from autoimmune diseases. * Patients suffering from hypersensitivity of this plant extract
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To measure the changes in parasite count in stool samples after treatment | six months |
Countries
Egypt
Contacts
CONTACTSalah
Outcome results
None listed